Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from STAT

12:38 EDT 19th June 2018 | BioPortfolio

Here are the most relevant search results for "STAT" found in our extensive news archives from over 250 global news sources.

More Information about STAT on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about STAT for you to read. Along with our medical data and news we also list STAT Clinical Trials, which are updated daily. BioPortfolio also has a large database of STAT Companies for you to search.

Showing News Articles 1–25 of 1,900+ from STAT

Tuesday 19th June 2018

Live chat at 12 p.m. ET: last week in CRISPR — cancer, patents, and a dip in the market

Join STAT's senior science writer, Sharon Begley, for an online chat about the latest developments with the genome-editing technology CRISPR. She'll take your questions about two new studies raising concerns…

With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’

Newly released data raise hopes that an experimental gene therapy may halt or even reverse the effects of Duchenne muscular dystrophy in certain patients.

STAT Plus: Pharmalittle: Valeant suffers a setback; CVS will use the Postal Service to deliver meds to your door

CVS struck a deal with the U.S. Postal Service to pick up prescriptions at its pharmacies and bring them to customer homes in one or two days.

Opinion: Why does my health insurer sabotage my efforts to manage my diabetes?

It makes no sense that health insurance will quickly cover kidney dialysis or an amputation for people with type 1 diabetes but they must fight for the things that will…

Opinion: An insider’s view of the myths and misconceptions behind 340B ‘reform’

I've worked with the 340B program for years. Pharma's attacks on it are wrong.

It’s not ‘all in your head’: When other doctors give up on patients, a boundary-breaking neurologist treats them

It was through her own experiences with mental illness that neurologist Dr. Alice Flaherty learned to care for patients that other physicians had given up on.

Monday 18th June 2018

7 questions to watch after criminal charges filed in the Theranos saga

So, what’s next for the Silicon Valley villains of the moment?

STAT Plus: Geron wants J&J to continue a drug development partnership, but new data weaken its case

Geron wants J&J to continue a drug development partnership, but new data weaken its case.

STAT Plus: Synthesizing genetic sequences could get faster, one DNA letter at a time

“The dream for me is to be able to print out genes overnight.”

STAT Plus: Pharmalittle: Chinese companies poaching big pharma talent; a battle over generic Suboxone looms

Multinational drug makers in China are fighting to hold on to top talent as senior local staff leave to join a booming domestic biotechnology sector drawing record investment.

CAR-T startup Allogene Therapeutics picks up veteran analyst Eric Schmidt as CFO

Veteran Cowen biotech analyst Eric Schmidt is joining Allogene Therapeutics, the new CAR-T cancer therapy startup, as its chief financial officer.

STAT Plus: New drug for spinal muscular atrophy shows positive results — and could be a threat to Biogen

An experimental drug from PTC and Roche could be a significant competitive threat to Biogen's Spinraza, the first chronic drug approved to treat patients with spinal muscular atrophy.

Opinion: Look to the EU’s new privacy law as a model for replacing the ‘confusing patchwork’ in the U.S.

The EU did something smart in overhauling its data privacy rules. The U.S. should follow.

Opinion: New Gardasil ad campaign gets it (mostly) right. It shouldn’t have taken a decade

While I was clicking through Snapchat, an ad for Merck's new Versed campaign for Gardasil stopped my thumb in its tracks.

Empty desks, squabbles, inexperienced staff: Exactly who is coordinating White House drug policy?

A year and a half into the Trump administration, it remains unclear who, besides Kellyanne Conway, is coordinating U.S. drug policy in the midst of an opioid crisis.

Donations of $4,500 overdose antidote were PR gold for drug maker — but some kits were close to expiring

As Kaleo raised the price of its Evzio overdose antidote, its donations to police agencies earned it a PR boon. But some of the donated naloxone was close to its…

Friday 15th June 2018

Theranos founder Elizabeth Holmes indicted for alleged fraud, out as CEO

A grand jury indicted CEO Elizabeth Holmes and her former No. 2 Sunny Balwani on Friday for alleged fraud at Theranos.

Theranos founder Elizabeth Holmes indicted for alleged fraud; out as CEO

A grand jury indicted CEO Elizabeth Holmes and her former No. 2 Sunny Balwani on Friday for alleged fraud at Theranos.

STAT Plus: China just approved its first cancer immunotherapy drug. Here’s what’s next in the pipeline

What's next in the pipeline for China's booming biotech sector?

STAT Plus: Investor coalitions finding success pushing drug makers on pricing and opioid distribution

Two investor coalitions are successfully using shareholder proposals to pressure drug makers and wholesalers to change their pricing and oversight of opioid distribution.

STAT Plus: Citing weak demand, IBM Watson Health to scale back hospital business

EXCLUSIVE: Top executives of IBM’s Watson Health division told employees at a meeting this week that they are scaling back part of their hospital business, citing softening demand in the…

Controversial NIH study of ‘moderate drinking’ will be terminated after scathing report

In a scathing report, an NIH task force found serious ethical and scientific lapses in the handling of a study funded by the alcohol industry.

STAT Plus: ‘Right-to-try’ law may have been unnecessary with previous success of FDA program, study argues

After years of emotional and legislative debate, the controversial "right-to-try" legislation is now law. But the authors of a new study suggest that effort may have been unnecessary.

STAT Plus: Up and down the ladder: The latest comings and goings

From new hires to departures and promotions, the latest comings and goings in the pharmaceutical industry.

STAT Plus: Pharmalittle: Bristol cancer drug is approved in China; Teva gets a headache over migraine trial flops

In a big win for Bristol-Myers Squibb, the Chinese Food and Drug Administration approved its Opdvid immunotherapy for second-line treatment of non-small cell lung cancer.


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks